Interactive panels
& exclusive interviews

to be live-streamed and recorded for over 3000 participants.



Covid-19 & transatlantic cooperation

OPENING PLENary: A story of a successful alliance

The race to a successful Covid-19 vaccine reflects the strong scientific and economic cooperation across the Atlantic. Such alliances are critical for further lifesaving innovation and ground-break technologies to emerge. But to do so, Europe must continue to ensure that the right conditions and incentives are in place. This opening panel will discuss the prospects and challenges Europe faces in building successful partnerships in the future, and how the Covid-19 crisis can serve as a catalyst to Europe’s role as a leader in global health.

Innovation in healthcare

first panel: Pandemic Preparedness & HERA

HERA is intended to provide the strategic steering during health emergencies. When a health emergency is declared, HERA will assume specific and extraordinary powers to coordinate critical stages of R&D activity until the end of the emergency. In long term, by bringing together sciences, industry and public authorities, HERA will aim at harmonizing the European biomedical research and development landscape for pandemic preparedness and response capacity. This needs to provide a structural system to enable the EU to anticipate and tackle future pandemics. The closing session will take stock of the discussion on the Commission’s proposal, expected to be published in the Fall of 2021.

SECOND panel: Central role of biotech in shaping the pharmaceutical landscape

Biotechnology has had a major impact on the healthcare landscape in the past years. This multidisciplinary field provides a variety of diagnoses, develops treatment to rare and complex conditions and resistance to a disease by producing several drugs and recombinant vaccines. Inevitably, this will greatly improve medicine as the sector is approaching a pivotal moment when genetics of the individual, will indicate the likely response of the disease to the biological treatment, paving the way towards a personalized medicine system.  Are our policies up to date to support this major shift?

THIRD panel: Gene therapy – the need for a paradigm shift

Gene Therapy is a new generation of medicine allowing us to target the underlying cause of a disease, potentially with just one treatment. These groundbreaking therapies will transform the treatment landscape globally within the next few years. However, the currently policy and regulatory framework is not set up to facilitate patient access. Changes in laws and regulations are urgently needed. What are some of the key challenges gene therapy developers are facing? What opportunities are ahead with the implementation of the EU’s Pharmaceutical Strategy for Europe as well as national reforms? This panel will bring together key policy-makers and stakeholders to ensure European health systems are ready to fully embrace this new generation of transformational medicines.

Digital healthcare

FOURTH panel: Digital transformation

The potential of digital transformation will drastically enhance the ability of doctors and hospitals in improving patient’s health and extend their life quality. Already today, thanks to wearable devices, vital real time data can be captured gaining a more accurate assessment of citizen’s health. The innovative shift towards telemedicine has facilitated patients’ access to health professionals.  Artificial intelligence will assist in analyzing vast amounts of data efficiently and will help the industry in becoming more sustainable, affordable and accessible. What stops this transformation from happening faster and what other challenges need to be determined?


FIFTH panel: Unlocking the capacities of health data space

The potential of health data is indisputably revolutionary. However, data is often not yet accessible in many European countries due to various reasons. Furthermore, processing and analysing sheer amounts of data, as well as gaining trust with the public and healthcare providers when it comes to sharing it, is one of its greatest challenges. How does the EU approach the initiative of building a home for health data? When it comes to the legal framework, does the basis of GDPR ensure sufficient levels of trust?

Global health & future preparedness

SIXTH panel: The global response to Covid-19 recovery through innovation and digital tools

Well before the pandemic, digital innovation has begun to shape the healthcare sector in countries around the world. COVID-19 has invigorated this process. As part of future pandemic response, innovation across public and private sectors will have an essential role to play. Appropriate support should be provided for countries globally, particularly to those who do not have the right tools and infrastructure in place to operationalize their national pandemic response plans, including vaccine development and production. However, this needs to go far beyond COVID-19 as we are moving towards future preparedness strategies. Embedding innovation at the heart of strengthened international cooperation will determine the resilience of our public health systems in the future.

SEVENTH Panel: Joining forces with Africa to foster health security

Stimulating cross-continental partnerships, beyond Europe, as part of forward planning strategy will live up to the famous saying of “No one is safe, until everyone is safe”. Our closest ally? The African Union. The continent`s misfortune with multiple outbreaks and infectious diseases should be a priority for the global community when it comes down to surveillance of emerging health threats. However, these unfortunate experiences entail existing local extensive expertise, which has not been able to be put in practice due to lack of tools and infrastructure. With the right type of investment and cooperation, it could turn these practices into potential research centers and thus vaccine manufacturing and production hubs.

closing session: Public-private partnerships to drive Europe`s health innovation

While international solidarity is imminent, strengthening EU’s own healthcare industry is paramount. The pandemic has demonstrated that, when compared to its competitors, Europe is lagging behind on pharmaceutical R&D, manufacturing and innovation capabilities, impeding its resilience. This session will debate whether a new policy framework is needed to address existing market failures to strengthen Europe’s innovative lead in breakthrough technologies.


Closing Remarks